BioVie Inc (NASDAQ:BIVI) announced that baseline data from a multicenter, randomized, placebo-controlled Phase 3 study of its Alzheimer’s Disease treatment was presented at the 83rd Scientific Sessions of the American Diabetes Association over the weekend in San Diego.
The company’s treatment, NE3107, is an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase. The Phase 3 trial is the largest study yet evaluating the safety and efficacy of NE3107 in patients with Alzheimer’s, the company said.
BioVie presented a poster titled, “Metabolic Dysregulation in Probable Alzheimer’s Disease,” which discussed the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and detailed baseline metabolic and inflammation characteristics from the study.
The presentation showed that 85% of patients had a high waist-to-hip ratio, 61% had hypertension, 52% had impaired glucose metabolism and 47% had some degree of insulin resistance. What’s more, 40% and 30% of patients had hypertriglyceridemia and hypercholesterolemia, respectively.
BioVie is developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
Previously, a Phase 2 study showed that NE3107 was associated with improvements in neurophysiological, neuropsychological, and biomarker status, and the treatment was associated with several patient and study partner-reported benefits, including improved mood and memory.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel